


**WHAT IS CLAIMED IS:**

1. A compound of the formula IIIB or a pharmaceutically acceptable salt thereof:



(IIIB)

wherein:

$n$  is an integer from 1 to 3;

$R_1$  and  $R_2$  are together alkylene of about 4 to about 8 carbons, optionally substituted with a group  $R'$ , where  $R'$  is selected from  $-OH$ , halogen,  $-NR_aR_b$ , in which  $R_a$  and  $R_b$  are independently selected from hydrogen,  $-C(=O)R_c$ ,  $-SO_2R_d$  and  $-C(=O)(CH_2)_mCO_2R_e$ , in which  $R_c$  and  $R_d$  are independently selected from alkyl, aryl and heteroaryl,  $R_e$  is hydrogen or alkyl and  $m$  is an integer from 1 to 3;

$Ar$  is unsubstituted phenyl or mono-, di-, tri-, or tetra-substituted phenyl, wherein said substituents are independently selected from halogen; alkyl; alkoxy; aryloxy; aralkyloxy; alkylene dioxide;  $-OH$ ;  $-SO_2R_f$  in which  $R_f$  is alkyl or aryl;  $-CN$ ; haloalkyl;  $-NR_gR_h$ , in which  $R_g$  and  $R_h$  are independently selected from hydrogen, alkyl,  $-C(=O)R_f$ ,  $-C(=O)-N(R_e)_2$ ,  $-S(O)_2R_f$ , and  $-(CH_2)_y-CO_2R_e$  in which  $y$  is an integer from 1 to 3;  $-S(O)_2N(R_i)(R_j)$ , in which  $R_i$  and  $R_j$  are each independently selected from hydrogen, alkyl optionally substituted with  $-CO_2R_e$ , aryl and aralkyl; or  $R_i$  and  $R_j$  together form  $-(CH_2)_2X(CH_2)_2-$ , where  $X$  is a direct bond,  $-CH_2-$ ,  $-NR_e-$ ,  $S$  or  $O$ ;

$R$  is hydrogen, halogen,  $-OH$ , alkoxy, or  $-NR_kR_l$ , where  $R_k$  and  $R_l$  are independently selected from hydrogen and alkyl.

2. A compound according to Claim 1 wherein:

n is 1;

$R_1$  and  $R_2$  are together unsubstituted alkylene of about 4 to about 6 carbons or alkylene of about 4 to about 6 carbons substituted with -OH or alkoxy;


Ar is unsubstituted phenyl or mono-, di-, tri-, or tetra-substituted phenyl, wherein said substituents are independently selected from alkyl; alkoxy; aralkyloxy; alkylene dioxide; -OH; haloalkyl;  $-NR_gR_h$ , in which  $R_g$  and  $R_h$  are independently selected from hydrogen, alkyl, and  $-S(O)_2R_f$ ;  $-S(O)_2N(R_i)(R_j)$ , where  $R_i$  and  $R_j$  are each independently selected from hydrogen, alkyl optionally substituted with  $-CO_2R_e$ , and aralkyl; or  $R_i$  and  $R_j$  together form  $-(CH_2)_2X(CH_2)_2-$ , where X is a direct bond,  $-NR_e-$ , S or O; and

R is hydrogen, halogen, -OH or alkoxy.

3. A compound according to Claim 2 wherein:

$R_1$  and  $R_2$  are together  $-(CH_2)_4-$  or  $-CH_2CH(OH)(CH_2)_2-$ ;

Ar is unsubstituted phenyl or mono-, di-, tri-, or tetra-substituted phenyl, wherein said substituents are independently selected from lower alkyl;  $-OCH_3$ ;  $-OCH_2C_6H_5$ ;  $-OCH_2O$ ; -OH;  $-CF_3$ ;  $-N(SO_2CH_3)_2$ ;  $-NH SO_2CH_3$ ;  $-SO_2N(CH_3)_2$ ;  $-SO_2N(CH_3)(CH_2CO_2H)$ ;  $-SO_2NHCH_3$ ;  $-SO_2N(CH_3)(CH_2C_6H_5)$ ;



where  $X'$  is  $-N(CH_3)-$  or  $-O-$ .

4. A compound according to Claim 1, with the provisos that:

when n is 1,  $R_1$  and  $R_2$  are unsubstituted alkylene of 4 carbons, and R is H, then Ar is other than unsubstituted phenyl, 2-aminophenyl, 3-aminophenyl, 4-aminophenyl, 2-amino-4,5-dichlorophenyl, 3,4-dichlorophenyl, 2-amino-4-trifluoromethylphenyl, 2- $N(SO_2CH_3)_2$ -phenyl, 3- $N(SO_2CH_3)_2$ -phenyl, 4- $N(SO_2CH_3)_2$ -phenyl, 2- $NH SO_2CH_3$ -phenyl, 3- $NH SO_2CH_3$ -phenyl, 4- $NH SO_2CH_3$ -phenyl, 2- $N(SO_2CH_3)_2$ -4,5-dichlorophenyl, 2- $N(SO_2CH_3)_2$ -4-trifluoromethylphenyl, 2- $NH SO_2CH_3$ -4-trifluoromethylphenyl, 4- $SO_2CH_3$ -phenyl, 2-methoxyphenyl, 2-hydroxyphenyl, 2-trifluoromethylphenyl, 3-trifluoromethylphenyl, 4-trifluoromethylphenyl, 3,4,5-trimethoxyphenyl, 2- $NH SO_2CH_3$ -4,5-dichlorophenyl, 2- $NHCH_2CO_2H$ -4-trifluoromethylphenyl, 2- $NH(SO_2C_6H_5)$ -phenyl, 3- $SO_2NHCH_3$ -4-chlorophenyl, 3- $SO_2NH_2$ -4-chlorophenyl, 3- $SO_2NHCH_3$ -4-fluorophenyl, 4- $SO_2NHCH_3$ -

phenyl, 3-SO<sub>2</sub>NHCH<sub>3</sub>-phenyl, 2-SO<sub>2</sub>NHCH<sub>3</sub>-phenyl, 2-SO<sub>2</sub>NHCH<sub>3</sub>-4-bromophenyl, 2-methoxy-3-SO<sub>2</sub>NHCH<sub>3</sub>-phenyl, 4-methoxy-3-SO<sub>2</sub>NHCH<sub>3</sub>-phenyl, 2-N(CH<sub>2</sub>CO<sub>2</sub>H)<sub>2</sub>-4-trifluoromethylphenyl, 3,4-dihydroxyphenyl, 3,4-dimethoxyphenyl, 2-SO<sub>2</sub>N(CH<sub>3</sub>)CH<sub>2</sub>C<sub>6</sub>H<sub>5</sub>-4,5-dimethoxyphenyl, 2-SO<sub>2</sub>N(CH<sub>3</sub>)CH<sub>2</sub>CO<sub>2</sub>H-3,4-dimethoxyphenol, 2-fluorophenyl, or 4-fluorophenyl;


when n is 1, R<sub>1</sub> and R<sub>2</sub> are unsubstituted alkylene of 4 carbons, and R is NH<sub>2</sub>, then Ar is other than 3,4-dichlorophenyl, 2-aminophenyl or 4-N(SO<sub>2</sub>CH<sub>3</sub>)<sub>2</sub>-phenyl;

when n is 1, R<sub>1</sub> and R<sub>2</sub> are -CH<sub>2</sub>CH(OH)(CH<sub>2</sub>)<sub>2</sub>-, and R is hydrogen, then Ar is other than 2-amino-4-trifluoromethylphenyl, aminophenyl, 4-SO<sub>2</sub>CH<sub>3</sub>-phenyl, 3,4,5-trimethoxyphenyl, 2-SO<sub>2</sub>NHCH<sub>3</sub>-phenyl, trifluoromethylphenyl, methylphenyl, halophenyl, methoxyphenyl, unsubstituted phenyl, 3-chloro-4-hydroxyphenyl, 4-benzyloxyphenyl, hydroxyphenyl, aminochlorophenyl, aminobromophenyl, acetamidophenyl, methylsulfonylaminophenyl, formamidophenyl or 3-amino-4-methoxyphenyl;

when n is 1, R<sub>1</sub> and R<sub>2</sub> are -CH<sub>2</sub>CH(OH)(CH<sub>2</sub>)<sub>2</sub>-, and R is hydroxy or amino, then Ar is other than trifluoromethylphenyl; and

when n is 1, R<sub>1</sub> and R<sub>2</sub> are unsubstituted alkylene of 4 carbons, and R is OH or OCH<sub>3</sub>, then Ar is other than 2-NHSO<sub>2</sub>CH<sub>3</sub>-phenyl, 4-trifluoromethyl or 3,4-dichlorophenyl.

5. A compound of the formula IIIB-i or a pharmaceutically acceptable salt thereof:



(IIIB-i)

wherein:

x is an integer from 0 to 4;

R" is hydrogen, fluoro, -OH, -NHC(=O)R<sub>c</sub>, -NHSO<sub>2</sub>R<sub>d</sub> and -NHC(=O)(CH<sub>2</sub>)<sub>m</sub>CO<sub>2</sub>R<sub>e</sub>, in which R<sub>c</sub> and R<sub>d</sub> are independently selected from alkyl, aryl and heteroaryl, R<sub>e</sub> is hydrogen or alkyl and m is an integer from 1 to 3

R<sub>3</sub> is independently selected from halogen; alkyl; alkoxy; aryloxy; aralkyloxy; alkylene dioxide; -OH; -SO<sub>2</sub>R<sub>f</sub> in which R<sub>f</sub> is alkyl or aryl; -CN; haloalkyl; -NR<sub>g</sub>R<sub>h</sub>, in which R<sub>g</sub> and R<sub>h</sub> are independently selected from hydrogen, alkyl, -C(=O)R<sub>f</sub>, -C(=O)-N(R<sub>e</sub>)<sub>2</sub>, -S(O)<sub>2</sub>R<sub>f</sub> in which R<sub>f</sub> is alkyl or aryl, and -(CH<sub>2</sub>)<sub>y</sub>-CO<sub>2</sub>R<sub>e</sub> in which y is an integer from 1 to 3; -S(O)<sub>2</sub>N(R<sub>i</sub>)(R<sub>j</sub>), in which R<sub>i</sub> and R<sub>j</sub> are each independently selected from hydrogen, alkyl optionally substituted with -CO<sub>2</sub>R<sub>e</sub>, aryl and aralkyl; or R<sub>i</sub> and R<sub>j</sub> together form -(CH<sub>2</sub>)<sub>2</sub>X(CH<sub>2</sub>)<sub>2</sub>-, where X is a direct bond, -CH<sub>2</sub>-, -NR<sub>e</sub>-, S or O;

R is hydrogen, halogen, -OH, alkoxy, or -NR<sub>k</sub>R<sub>l</sub>, where R<sub>k</sub> and R<sub>l</sub> are independently selected from hydrogen and alkyl.


6. A compound according to Claim 5 wherein:

R<sub>3</sub> is independently selected from alkyl; alkoxy; aralkyloxy; alkylene dioxide; -OH; haloalkyl; -NR<sub>g</sub>R<sub>h</sub>, in which R<sub>g</sub> and R<sub>h</sub> are independently selected from hydrogen, alkyl, and -S(O)<sub>2</sub>R<sub>f</sub>; -S(O)<sub>2</sub>N(R<sub>i</sub>)(R<sub>j</sub>), in which R<sub>i</sub> and R<sub>j</sub> are each independently selected from hydrogen, alkyl optionally substituted with -CO<sub>2</sub>R<sub>e</sub>, and aralkyl; or R<sub>i</sub> and R<sub>j</sub> together form -(CH<sub>2</sub>)<sub>2</sub>X(CH<sub>2</sub>)<sub>2</sub>-, where X is a direct bond, -NR<sub>e</sub>-, S or O;

R is hydrogen, halogen, -OH or alkoxy.

7. A compound according to Claim 6 wherein:

R<sub>3</sub> is independently selected from lower alkyl; -OCH<sub>3</sub>; -OCH<sub>2</sub>C<sub>6</sub>H<sub>5</sub>; -OCH<sub>2</sub>O-; -OH; CF<sub>3</sub>; -N(SO<sub>2</sub>CH<sub>3</sub>)<sub>2</sub>; -NHSO<sub>2</sub>CH<sub>3</sub>; -SO<sub>2</sub>N(CH<sub>3</sub>)<sub>2</sub>; -SO<sub>2</sub>N(CH<sub>3</sub>)(CH<sub>2</sub>CO<sub>2</sub>H); -SO<sub>2</sub>NHCH<sub>3</sub>; -SO<sub>2</sub>N(CH<sub>3</sub>)(CH<sub>2</sub>C<sub>6</sub>H<sub>5</sub>);



where X' is -N(CH<sub>3</sub>)- or -O-.

8. A compound according to Claim 5 wherein substituent R" is in the S configuration.

9. A compound according to Claim 5 with the provisos that:

when R and R" are H, then the phenyl ring and (R<sub>3</sub>)<sub>x</sub> together are other than unsubstituted phenyl, 2-aminophenyl, 3-aminophenyl, 4-aminophenyl, 2-N(SO<sub>2</sub>CH<sub>3</sub>)<sub>2</sub>-phenyl, 3-N(SO<sub>2</sub>CH<sub>3</sub>)<sub>2</sub>-phenyl, 4-N(SO<sub>2</sub>CH<sub>3</sub>)<sub>2</sub>-phenyl, 2-NHSO<sub>2</sub>CH<sub>3</sub>-phenyl, 3-NHSO<sub>2</sub>CH<sub>3</sub>-phenyl, 4-NHSO<sub>2</sub>CH<sub>3</sub>-phenyl, 4-SO<sub>2</sub>CH<sub>3</sub>-phenyl, 2-methoxyphenyl, 2-hydroxyphenyl, 2-trifluoromethylphenyl, 3-trifluoromethylphenyl, 4-trifluoromethylphenyl, 3-SO<sub>2</sub>NHCH<sub>3</sub>-phenyl, 2-SO<sub>2</sub>NHCH<sub>3</sub>-phenyl, 4-SO<sub>2</sub>NHCH<sub>3</sub>-phenyl, 2-fluorophenyl, 4-fluorophenyl, 3,4-dichlorophenyl, 2-amino-4-trifluoromethylphenyl, 2-N(SO<sub>2</sub>CH<sub>3</sub>)<sub>2</sub>-4-trifluoromethylphenyl, 2-NHSO<sub>2</sub>CH<sub>3</sub>-4-trifluoromethylphenyl, 2-NHCH<sub>2</sub>CO<sub>2</sub>H-4-trifluoromethylphenyl, 3-SO<sub>2</sub>NHCH<sub>3</sub>-4-chlorophenyl, 3-SO<sub>2</sub>NH<sub>2</sub>-4-chlorophenyl, 3-SO<sub>2</sub>NHCH<sub>3</sub>-4-fluorophenyl, 2-SO<sub>2</sub>NHCH<sub>3</sub>-4-bromophenyl, 2-methoxy-3-SO<sub>2</sub>NHCH<sub>3</sub>-phenyl, 4-methoxy-3-SO<sub>2</sub>NHCH<sub>3</sub>-phenyl, 2-N(CH<sub>2</sub>CO<sub>2</sub>H)<sub>2</sub>-4-trifluoromethylphenyl, 3,4-dihydroxyphenyl, 3,4-dimethoxyphenyl, 2-amino-4,5-dichlorophenyl, 2-N(SO<sub>2</sub>CH<sub>3</sub>)<sub>2</sub>-4,5-dichlorophenyl, 3,4,5-trimethoxyphenyl, 2-NHSO<sub>2</sub>CH<sub>3</sub>-4,5-dichlorophenyl, or 2-SO<sub>2</sub>N(CH<sub>3</sub>)CH<sub>2</sub>CO<sub>2</sub>H-4,5-dimethoxyphenyl, 2-SO<sub>2</sub>N(CH<sub>3</sub>)CH<sub>2</sub>CO<sub>2</sub>H-3,4-dimethoxyphenol;

when R" is H and R is NH<sub>2</sub>, then the phenyl ring and (R<sub>3</sub>)<sub>x</sub> together are other than 3,4-dichlorophenyl, 2-aminophenyl or 4-N(SO<sub>2</sub>CH<sub>3</sub>)<sub>2</sub>-phenyl;

when R" is OH, and R is hydrogen, then the phenyl ring and (R<sub>3</sub>)<sub>x</sub> together are other than unsubstituted phenyl, 2-amino-4-trifluoromethylphenyl, aminophenyl, 4-SO<sub>2</sub>CH<sub>3</sub>-phenyl, 3,4,5-trimethoxyphenyl, 2-SO<sub>2</sub>NHCH<sub>3</sub>-phenyl, trifluoromethylphenyl, methylphenyl, halophenyl, methoxyphenyl, 3-chloro-4-hydroxyphenyl, 4-benzyloxyphenyl, hydroxyphenyl, aminochlorophenyl, aminobromophenyl, acetamidophenyl, methylsulfonylaminophenyl, formamidophenyl or 3-amino-4-methoxyphenyl

when R" is OH and R is hydroxy or amino, then the phenyl ring and (R<sub>3</sub>)<sub>x</sub> together are other than trifluoromethylphenyl; and

when R" is H and R is OH or OCH<sub>3</sub>, then the phenyl ring and (R<sub>3</sub>)<sub>x</sub> together are other than 2-NHSO<sub>2</sub>CH<sub>3</sub>-phenyl, 4-trifluoromethylphenyl or 3,4-dichlorophenyl.

10. A compound selected from the group consisting of:

2-(3-N-Methylsulfonamido-3-amino-4-methoxyphenyl)-N-methyl-N-[(1S)-1-phenyl-2-(1-pyrrolidinyl)ethyl]acetamide methane sulfonate;

2-(3-N-Methylsulfonamido-3-amino-4-benzyloxyphenyl)-N-methyl-N-[(1S)-1-phenyl-2-(1-pyrrolidinyl)ethyl]acetamide;

2-(3-N-Methylsulfonamido-3-amino-4-hydroxyphenyl)-N-methyl-N-[(1S)-1-phenyl-2-(1-pyrrolidinyl)ethyl]acetamide;

2-(2-N-Methylsulfonamido-2-aminophenyl)-N-methyl-N-[(1S)-1-phenyl-2-[1-(3S)-(3-hydroxypyrrolidinyl)ethyl]]acetamide;

2-(2-N-Methylsulfonamido-2-amino-4-trifluoromethylphenyl)-N-methyl-N-[(1S)-1-phenyl-2-[1-(3S)-(3-hydroxypyrrolidinyl)ethyl]]acetamide;

2-(3-N-Methylsulfonamido-3-amino-4-methoxyphenyl)-N-methyl-N-[(1S)-1-phenyl-2-[1-(3S)-(3-hydroxypyrrolidinyl)ethyl]]acetamide;

2-(2-N-Methylsulfonamido-2-aminophenyl)-N-methyl-N-1-(4-methoxyphenyl)-2-(1-pyrrolidinyl)ethyl]acetamide;

(R,S)-2-(2-N-Methylsulfonamido-2-aminophenyl)-N-methyl-N-1-(4-hydroxyphenyl)-2-(1-pyrrolidinyl)ethyl]acetamide;

(S)-2-(2-N-Methylsulfonamido-2-aminophenyl)-N-methyl-N-1-(4-hydroxyphenyl)-2-(1-pyrrolidinyl)ethyl]acetamide;

2-(3-N-Bis-methylsulfonamido-3-amino-4-hydroxyphenyl)-N-methyl-N-[(1S)-1-phenyl-2-(1-pyrrolidinyl)ethyl]acetamide;

2-[2-(N-Benzyl-N-methylsulfamoyl)-4,5-methylenedioxyphenyl]-N-methyl-N-[(1S)-1-phenyl-2-[(1-pyrrolidinyl)ethyl]]acetamide;

2-[2-(N-Dimethylsulfamoyl)-4,5-methylenedioxyphenyl]-N-methyl-N-[(1S)-1-phenyl-2-[(1-pyrrolidinyl)ethyl]]acetamide;

2-[2-(N-Dimethylsulfamoyl)-4,5-methylenedioxyphenyl]-N-methyl-N-[(1S)-1-phenyl-2-[1-(3S)-(3-hydroxypyrrolidinyl)ethyl]]acetamide;

2-[2-(N-Pyrrolidinesulfamoyl)-4,5-dimethoxyphenyl]-N-methyl-N-[(1S)-1-phenyl-2-[(1-pyrrolidinyl)ethyl]]acetamide;

2-[2-(N-Pyrrolidinesulfamoyl)-4,5-dimethoxyphenyl]-N-methyl-N-[(1S)-1-phenyl-2-[1-(3S)-(3-hydroxypyrrolidinyl)ethyl]]acetamide;

2-[2-(N-Dimethylsulfamoyl)-4,5-dimethoxyphenyl]-N-methyl-N-[(1S)-1-phenyl-2-[(1-pyrrolidinyl)ethyl]]acetamide;

2-[2-(N-Dimethylsulfamoyl)-4,5-dimethoxyphenyl]-N-methyl-N-[(1S)-1-phenyl-2-[1-(3S)-(3-hydroxypyrrolidinyl)ethyl]]acetamide;

2-[2-[N-(4-Methylpiperazine)]sulfamoyl)-4,5-dimethoxyphenyl]-N-methyl-N-[(1S)-1-phenyl-2-[1-(pyrrolidinyl)ethyl]]acetamide;

2-[2-[N-(4-Methylpiperazine)sulfamoyl]-4,5-dimethoxyphenyl]-N-methyl-N-[(1S)-1-phenyl-2-[1-(3S)-(3-hydroxypyrrolidinyl)ethyl]]acetamide;

2-[2-N-(Morpholinesulfamoyl)-4,5-dimethoxyphenyl]-N-methyl-N-[(1S)-1-phenyl-2-[1-(pyrrolidinyl)ethyl]]acetamide;

2-[2-N-(Morpholinesulfamoyl)-4,5-dimethoxyphenyl]-N-methyl-N-[(1S)-1-phenyl-2-[1-(3S)-(3-hydroxypyrrolidinyl)ethyl]]acetamide;

N-Methyl-[[2-(N-sulfamoyl)-4,5-dimethoxyphenyl]-N-methyl-N-[(1S)-1-phenyl-2-[1-(pyrrolidinyl)ethyl]]acetamido]glycine;

2-[2-(N-Pyrrolidinesulfamoyl)-3,4,5-trimethoxyphenyl]-N-methyl-N-[(1S)-1-phenyl-2-[(1-pyrrolidinyl)ethyl]]acetamide;

2-[2-(N-t-Butylsulfamoyl)-3,4,5-trimethoxyphenyl]-N-methyl-N-[(1S)-1-phenyl-2-[(1-pyrrolidinyl)ethyl]]acetamide;

2-[2-(N-Methylsulfamoyl)-4-methoxyphenyl]-N-methyl-N-[(1S)-1-phenyl-2-[(1-pyrrolidinyl)ethyl]]acetamide;

2-[4-N-(Methylsulfamoyl)-phenyl]-N-methyl-N-[(1S)-1-phenyl-2-[1-(3S)-(3-hydroxypyrrolidinyl)ethyl]]acetamide;

2-[2-(N-Methylsulfamoyl)-phenyl]-N-methyl-N-[1-(2-fluorophenyl)-2-[(1-pyrrolidinyl)ethyl]]acetamide; and

2-[2-(N-Benzyl-N-methylsulfamoyl)-4,5-dimethoxyphenyl]-N-methyl-N-[(1S)-1-phenyl-2-[(1-pyrrolidinyl)ethyl]]acetamide;

or a pharmaceutically acceptable salt thereof.

11. A compound according to Claim 10 which is selected from the group consisting of

2-[2-(N-Methylsulfamoyl)-4-methoxyphenyl]-N-methyl-N-[(1S)-1-phenyl-2-[(1-pyrrolidinyl)ethyl]]acetamide; and

(S)-2-(2-N-Methylsulfonamido-2-aminophenyl)-N-methyl-N-1-(4-hydroxyphenyl)-2-(1-pyrrolidinyl)ethyl]acetamide;

or a pharmaceutically acceptable salt thereof.

12. A compound according to Claim 11 which is 2-[2-(N-Methylsulfamoyl)-4-methoxyphenyl]-N-methyl-N-[(1S)-1-phenyl-2-[(1-pyrrolidinyl)ethyl]]acetamide or a pharmaceutically acceptable salt thereof.

13. A compound according to Claim 11 which is (S)-2-(2-N-Methylsulfonamido-2-aminophenyl)-N-methyl-N-1-(4-hydroxyphenyl)-2-(1-pyrrolidinyl)ethyl]acetamide or a pharmaceutically acceptable salt thereof.
14. A pharmaceutical composition comprising a compound according to Claim 1 together with a pharmaceutically acceptable carrier.
15. A pharmaceutical composition comprising a compound according to Claim 5 together with a pharmaceutically acceptable carrier.
16. A pharmaceutical composition comprising a compound according to Claim 10 together with a pharmaceutically acceptable carrier.
17. A method of treating hyperalgesia in a patient comprising administering to said patient an effective amount of a compound according to Claim 1.
18. A method of treating hyperalgesia in a patient comprising administering to said patient an effective amount of a compound according to Claim 5.
19. A method of treating hyperalgesia in a patient comprising administering to said patient an effective amount of a compound according to Claim 10.